Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$69.06−5.12 (-6.90%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Inhibrx Biosciences's revenue for the twelve months ending Dec 31, 2025 was $1.30M, up 550.0% year over year. For fiscal 2025 it was $1.30M, up 550.0% from the year before. The highest annual figure on record is $13.21M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30M | +550.0% |
| FY2024 | Dec 31, 2024 | $200.00K | -88.9% |
| FY2023 | Dec 31, 2023 | $1.80M | -17.9% |
| FY2022 | Dec 31, 2022 | $2.19M | -69.7% |
| FY2021 | Dec 31, 2021 | $7.23M | -43.9% |
| FY2020 | Dec 31, 2020 | $12.89M | -2.4% |
| FY2019 | Dec 31, 2019 | $13.21M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.00M | +53.8% |
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $1.30M | +1200.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $100.00K | -93.9% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $100.00K | +233.3% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.63M | +496.4% |
| Q3 FY2023 | Sep 30, 2023 | $119.00K | -57.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.00K | -95.8% |
| Q1 FY2023 | Mar 31, 2023 | $17.00K | -98.2% |
| Q4 FY2022 | Dec 31, 2022 | $274.00K | -90.4% |
| Q3 FY2022 | Sep 30, 2022 | $278.00K | -89.0% |
| Q2 FY2022 | Jun 30, 2022 | $711.00K | -25.5% |
| Q1 FY2022 | Mar 31, 2022 | $929.00K | +4.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.86M | +2.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.53M | -57.1% |
| Q2 FY2021 | Jun 30, 2021 | $954.00K | -71.4% |
| Q1 FY2021 | Mar 31, 2021 | $889.00K | +1.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.78M | +955.5% |
| Q3 FY2020 | Sep 30, 2020 | $5.90M | +384.1% |
| Q2 FY2020 | Jun 30, 2020 | $3.34M | – |
| Q1 FY2020 | Mar 31, 2020 | $872.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $263.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $1.22M | – |
See a number that looks wrong?